Plus Therapeutics Soars 14.04% on FDA Name Acceptance

On March 25, 2025, Plus Therapeutics experienced a significant surge in its stock price, rising 14.04% in pre-market trading.

This surge can be attributed to the FDA's conditional acceptance of REYOBIQ™ as the proprietary name for the company's lead drug. This development is a major milestone for Plus Therapeutics, as it brings the company one step closer to bringing its targeted radiotherapeutics for CNS cancers to market. The acceptance of the proprietary name is a crucial step in the regulatory process and indicates that the FDA is satisfied with the drug's safety and efficacy profile.

Additionally, the positive market sentiment surrounding the biotech sector has likely contributed to the stock's rise. Investors are increasingly optimistic about the potential of targeted radiotherapeutics, and Plus Therapeutics' focus on CNS cancers positions it well to capitalize on this trend. The company's strong pipeline and experienced management team also instill confidence in investors, further driving the stock's upward momentum.